TickerTalks
Browse all tickers →
TickerTalks›$ABT
ABABT

Abbott Laboratories

Strong FundamentalsStrong FundamentalsRevenue growing 8% YoY at strong marginsStreet coverage with positive forward estimatesConsistent chatter on X (253/wk), no spike
$ABT·$172B·Medical - Devices·Healthcare
$104.88+0.2%YTD-15.9%1Y-17.8%
Price updated 6h ago·X counts updated 5d ago
ABABT
$ABTAbbott Laboratories
$104.88+0.19%253 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $ABT on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

253X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $ABT's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data6 posts analyzed · as of 2026-10-02

The $ABT feed is Arcblock, not Abbott — holders are promoting the "decentralized one-stop shop" with weekly RSI breaking out and modeling a $1B market cap = $10/token price. The pitch is AI agents and specialized skills marketplace being built on Arcblock. No bearish voice in the sample; the thread is community anticipation of a trending breakout.

Read what X is saying about $ABT

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $ABT — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersWinding up for a moveAI verdict · as of 2026-10-03

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Abbott down 22% YTD on the NEC litigation overhang — now coiling into Oct 21 earnings with the business still printing +7% YoY.

Abbott is one of the largest diversified medical-devices and healthcare companies — Diagnostics, Medical Devices (including Freestyle Libre), Established Pharma, and Nutrition. The stock has lost 22% YTD on the preterm-formula NEC litigation overhang, now coiling into Oct 21 Q3 earnings.

  • The business is doing fine: Q1 2026 revenue of $11.2B at +7.8% YoY with 56% gross margins and 16% operating margins — the Libre CGM franchise is still growing, with 2026 consensus EPS of $5.20.
  • The NEC litigation partially settled: an Aug 20 Reg FD press release confirmed a partial settlement, which removes some but not all of the overhang — the uncertainty discount is the specific reason for the YTD drawdown.
  • 25x trailing is reasonable for a healthcare compounder with a durable Libre franchise: 2027 forward P/E drops to ~17x on consensus $5.72 EPS, which is cheap for a quality compounder that just resolved part of the legal overhang.

An Oct 21 Q3 print with Libre growth above 20% YoY and clean 2026 guide re-rates it off the lows; a worse-than-expected NEC settlement update or a Libre growth deceleration and the coil becomes a drift.

What to watch: Oct 21 Q3 earnings — Libre CGM revenue growth above 20%, any new NEC settlement commentary, Diagnostics segment organic growth, and 2026 guide. A clean beat with NEC resolution clarity re-rates it; a Libre growth deceleration or NEC escalation extends the drawdown.

On the calendar: 2026-10-21 — Q3 2026 earnings

sentiment mismatched asset

Read the AI verdict on $ABT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Sells diagnostics, cardiovascular devices, continuous glucose monitors (FreeStyle Libre), and branded generics across 160+ countries.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $ABT.

Medical - Devices · Healthcare

Aging population demographics and AI-assisted device adoption (smart implants, continuous glucose monitors, digital health integration) are the long-cycle structural drivers. Reimbursement timing for new modalities (CMS coverage decisions) and procedure volume recovery from COVID-era deferred care shape the 2026 revenue trajectory.

What this means for $ABT

Direct beneficiary — Sells diagnostics, cardiovascular devices, continuous glucose monitors (FreeStyle Libre), and branded generics across 160+ countries.

Industry benchmark

21-name peer basket
+10.8%YTD
+0.8%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
25.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
6.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
18.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
4.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
12.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
56.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 16, 2026$1.31$1.28+2.3%
Q1 2026Apr 16, 2026$1.15$1.14+0.9%
Q4 2025Jan 22, 2026$1.50$1.500.0%
Q3 2025Oct 15, 2025$1.30$1.300.0%
Next earningsWed, Oct 21·consensus EPS $1.42

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$11.2B+7.8%56.3%16.5%$0.62$916.0M
Q4 FY25$11.5B+4.4%57.0%19.6%$1.02$2.6B
Q3 FY25$11.4B+6.9%55.7%18.1%$0.94$2.3B
Q2 FY25$11.1B+7.4%56.4%18.4%$1.02$1.5B

Forward consensus

5-year forecast · up to 21 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$50.3B$50.2B – $50.4B$5.51$5.47 – $5.5621
FY27$54.7B$53.6B – $55.3B$6.06$6.00 – $6.1821
FY28$58.5B$53.8B – $59.8B$6.73$4.51 – $7.6020
FY29$63.1B$60.2B – $63.9B$7.45$7.00 – $7.5810
FY30$67.8B$64.6B – $68.7B$8.26$7.76 – $8.3910

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.46%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-0.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+2.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 1.7B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.585-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 2John A. MccoyPresident27 sh$3KSellAug 25Robert B FordCEO398.8K sh$46.2MSellAug 11Louis H. MorronePresident5.8K sh$643KBuyMay 7John G StrattonDirector2.0K sh$174KBuyApr 27Daniel J StarksDirector10.0K sh$927KBuyApr 23Philip P BoudreauCFO2.2K sh$201K
+ 31 other (22 awards · 5 inkinds · 3 discretionarys · 1 exempt) in window

See when $ABT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDAug 208-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Abbott Laboratories disclosed a partial settlement of its ongoing necrotizing enterocolitis (NEC) litigation involving its specialty preterm infant formula products, announced via a Reg FD press release on August 20, 2026. Abbott faces numerous lawsuits alleging preterm infants developed NEC from its formulas, including a July 2024 Missouri jury verdict against Abbott. The settlement covers a portion of the pending litigation; specific settlement amounts are not disclosed in the filing body. This is material: the NEC liability represents a multi-billion-dollar exposure for Abbott, and any partial resolution — while positive — leaves significant litigation risk outstanding.

3New insider — initial holdingsApr 283
AI summary

Kevin T. Conroy, newly appointed director of Abbott Laboratories (ABT), filed an initial Form 3 as of April 24, 2026. Table I indicates beneficial ownership of Abbott common shares, but the specific count is truncated in the excerpt. Routine Section 16(a) initial ownership disclosure for a new director; administrative and non-material.

8-KOfficer or director changeApr 278-K — Item 5.02: Officer or director change · Item 5.03: Charter amendment · Item 5.07: Shareholder vote
AI summary

Abbott Laboratories (ABT) held its Annual Meeting on April 24, 2026 at which stockholders approved the 2026 Incentive Stock Program (replacing the 2017 Program) and elected Kevin Conroy to the Board. The 2026 Program authorizes up to 140,000,000 Abbott shares plus shares released from the 2017 Program, with full-value award shares counting as three shares against the reserve, and permits stock options, RSUs, performance awards, and other share-based grants. A new Amended and Restated By-Laws also appear to be an associated item (Item 5.03). The 2026 Program represents substantial new equity compensation capacity for Abbott and is a routine annual governance action.

+ 7 other (2 10-Qs · 1 earnings 8-K · 1 11-K · 1 SD) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Countdown to Abbott (ABT) Q3 Earnings: A Look at Estimates Beyond Revenue and EPSzacks.com·17h agoAbsolute Software Co. (ABT.TO) (TSE:ABT) Stock Crosses Above 200 Day Moving Average – What’s Next?defenseworld.net·1d ago3 Overlooked Healthcare Dividend Stocks That Could Keep Paying for Decades247wallst.com·2d agoAbbott Laboratories $ABT Stock: Krilogy Financial LLC Increases Stakedefenseworld.net·2d agoLongleaf Partners Global Fund Q3 2026 Portfolio Reviewseekingalpha.com·2d ago

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TMDX$MDT$QSI$BIO$PACB$BSX$BFLY$GEHC
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport